Lukáš Jiří

Born 31. October, 1961

• Cell & cancer biology
• Honorary member of the Learned Society since 2005

Educational and professional preparation:

• (1981-86) Veterinary University, Brno, Czech Republic
• (1987-90) Institute of Systematic and Ecological Biology, Czech Academy of Sciences, Brno, Czech Republic
• (1990 & 1991) Department of Biochemistry (Paul Nurse), Oxford, UK
• (1992-93) Cell Cycle Group (Giulio Draetta), EMBL, Heidelberg, Germany
• Since 2005: Director, Centre for Genotoxic Stress Research
• Institute of Cancer Biology, Danish Cancer Society

Research interests:

• Regulation of the mammalian cell division cycle and its response to genotoxic stress
• Non-invasive imaging of molecular events in living mammalian cells

Notable awards:

• Fellowships: EMBO, UICC, ICRF
• Grants: Human Frontier Scientific Programme; European Union (FP6), European Science Foundation, Danish Cancer Society; Danish National Research Foundation.
• Young Danish Cancer Researcher Prize (1995)
• Elected EMBO Member (2002)
• Alfred Benzons Foundation Prize (2002)
• Novo Nordisk Foundation Prize (2003)
• G. J. Mendel Honorary Medal (2003)
• Associated professor, Aarhus University (2005)
• Honorary member of the Learned Society of the Czech Republic (2005)
• Senior Researcher Prize, Danish Cancer Society (2006)

Patents:

• International patent on the Cdc25A DNA damage checkpoint pathway as a target for cancer therapeutics.

Selected publications:

97 research papers in peer reviewed journals; 25 review articles; 4 book chapters.
The references of 10 key papers are provided below:

• Lukas, J., Parry, D., Aagaard, L., Mann, D.J., Bartkova, J., Strauss, M., Peters, G., and Bartek, J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375, 503-506 (1995).
• Lukas, C., Sørensen, C.S., Kramer, E., Santoni-Rugiu, E., Lindeneg, C., Peters, J. M., Bartek, J., and Lukas, J. Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 401, 815-818 (1999).
• Mailand, N., Falck, J., Lukas, C., Syljuåsen R., Welcker, M., Bartek, J., and Lukas, J. Rapid destruction of human Cdc25A in response to DNA damage. Science 288, 1425-1429 (2000).
• Falck, J., Mailand, N., Syljuasen, R. G., Bartek, J. & Lukas, J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842-847 (2001).
• Sørensen, C. S., Syljuåsen, R. G., Falck, J., Schroeder, T., Rönnstrand, L., Zhou, B. B., Bartek, J., and Lukas, J. Chk1 regulates the S-phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 3, 247-258 (2003).
• Lukas, C., Falck, J., Bartkova, J., Bartek, J., and Lukas, J. Distinct spatio-temporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nature Cell Biology 5, 255-260 (2003).
• Lukas, J., and Bartek, J. The heart of the cycle. Nature, 432, 564-567 (2004).
• Bartkova, J., Horejsi, Z., Koed, K., Guldberg, P., Krämer, A., Sehested, M., Nesland, J., Lukas, C., Ørntoft, T., Lukas, J., and Bartek. J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature, 434, 864-870 (2005).
• Bartek, J., and Lukas, J. Balancing life-or-death decisions. Science, 314, 261-262 (2006).
• Mailand, N., Bekker-Jensen, S., Bartek, J., and Lukas, J. Destruction of Claspin by SCF ^TrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Molecular Cell, 23, 307-318 (2006).